




INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

P. Mahoney

Dated


19 August 2003

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

11 OCT 2002

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1. Your reference

2. Patent application number
(The Patent Office will fill in this part)

0223730.3

3. Full name, address and postcode of the
or of each applicant
(underline all surnames)

NOVARTIS AG
LICHTSTRASSE 35
4056 BASEL
SWITZERLAND

7125487005

Patent ADP number (if you know it)

If the applicant is a corporate body,
give the country/state of its
incorporation

SWITZERLAND

4. Title of invention

Organic compounds

5. Name of your agent (if you have one)
"Address for service" in the United
Kingdom to which all correspondence
should be sent
(including the postcode)

Novartis Pharmaceuticals UK Ltd
Patents and Trademarks
Wimblehurst Road
HORSHAM
West Sussex
RH12 5AB
ADP No 074852200

Patents ADP number (if you know it)

6. If you are declaring priority from one
ore more earlier patent applications,
give
the country and the date of filing of
the or of each of these earlier
applications and (if you know it) the or
each application number

Country

Priority application
number
(if you know it)

Date of filing
(day/month/year
)

7. If this application is divided or
otherwise derived from an earlier UK
application, give the number and the
filing date of the earlier application

Number of earlier
application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of
right to grant of a patent required in
support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an
inventor, or
- b) there is an inventor who is not named as
an applicant, or
- c) any named applicant is a corporate
body.

(see note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 17

Claim(s) 3

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) One

Request for substantive examination (*Patents Form 10/77*)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co.

B.A. Yorke & Co.

11 October 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham

020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes


- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

- 1 -


Organic Compounds

The present invention relates to novel quinazolinone derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

More particularly the present invention provides, in a first aspect, a compound of formula I






wherein



R^2 is hal; nitro; C_1 - C_6 alkylcarbonyl; C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl;

R^3 is C_1 - C_6 alkyl; C_1 - C_6 alkoxy or amino;

R^4 is H; hal; hydroxy; C_1 - C_6 alkyl; C_1 - C_6 alkoxy; C_1 - C_6 alkoxy C_1 - C_6 alkoxy; C_1 - C_6 alkoxy C_1 - C_6 alkoxy C_1 - C_6 alkoxy; C_1 - C_6 alkoxy C_1 - C_6 alkyl; halogeno C_1 - C_6 alkoxy; C_3 - C_7 cycloalkyl C_1 - C_6 alkoxy that may be substituted at the cycloalkyl residue by C_1 - C_6 alkyl; C_1 - C_6 alkoxycarbonyl; C_3 - C_6 alkenyloxy; $(C_1$ - C_6 alkyl) $_2$ N- C_1 - C_6 alkoxy; C_1 - C_6 alkyl-sulfanyl; C_1 -



wherein n is 0, 1, 2, 3, 4, 5 or 6;

R^5 , R^6 and R^{11} , independently, are H; hal; C_1 - C_6 alkoxy; or C_1 - C_6 alkyl;
 R^7 , R^8 and R^{12} , independently, are H or C_1 - C_6 alkyl; and
 R^9 and R^{10} , independently, are H or hal;
 in free base or acid addition salt form.


Terms used in this specification have the following meanings:

" C_1 - C_6 alkyl" denotes straight chain or branched C_1 to C_6 -alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl.

"Hal" denotes halogen which may be I, Br, Cl or F.

Compounds of the invention exist in free or salt, e.g. acid addition salt form. The invention is to be understood as including the compounds of formula I in free as well as in salt form, e.g. as trifluoroacetate or hydrochloride salt. Suitable pharmaceutically acceptable acid addition salts for pharmaceutical use in accordance with the invention include in particular the hydrochloride salt.

In formula I the following significances are preferred independently, collectively or in any combination or sub-combination:



- (b) R^2 is isopropyl;
 - (c) R^3 is methyl or amino; more preferably methyl;
 - (d) R^4 is in meta position as defined above; or more preferably R^4 is in meta position and is C_1 - C_4 alkoxy or C_3 - C_4 cycloalkyl- C_1 - C_4 alkoxy;
 - (e) R^5 is in para position and is hal; more preferably Cl;
 - (f) R^6 is H or halogen; more preferably H;
 - (g) R^7 or R^8 is H or methyl; more preferably methyl;
 - (h) R^{11} is C_1 - C_4 alkoxy; more preferably methoxy;
 - (i) R^{12} is methyl;
 - (k) n is 0 or 1; and
- R^9 and R^{10} are as defined above.

In addition to the foregoing the present invention also provides a process for the production of a compound of formula I which process comprises coupling suitable starting compounds applying methods known to the skilled artisan.

More particularly the invention provides a process for the production of a compound of formula I comprising the steps of:

a) for the production of a compound of formula I wherein R^3 is not NH_2 , reacting a compound of formula II



wherein

R^1 and R^2 are as defined in formula I,
with a compound of formula III



wherein R^3 is as defined in formula I; or

b) for the production of a compound of formula I wherein R^3 is NH_2 , reacting a compound of formula IV



wherein R^1 and R^2 are as defined in formula I,
with 2-ethyl-2-thiopseudourea hydrobromide;
and recovering the obtained compound in free or in salt form, e.g. acid addition salt form.

Compounds of formula I resulting from the above process may be further derivatised, e.g. as described in Example 1, i.e. for the conversion of 6-(4-chloro-3-fluoro-phenyl)-7-isopropyl-2-

methoxy-3H-quinazolin-4-one into 6-(4-chloro-3-cyclopropylmethoxy-phenyl)-7-isopropyl-2-methoxy-3H-quinazolin-4-one.

Compounds of formula III are known or may be prepared from corresponding known compounds, e.g. as described in Examples 1 or 2. Compounds of formula IV are known or may be prepared from corresponding known compounds, e.g. as described in Example 59.

Compounds of formula II are new and also an embodiment of the present invention. They may be prepared from corresponding known compounds according to the general knowledge of a person skilled in the art, e.g. as described in Examples 1 and 2.

The compounds of formula I and their pharmaceutically acceptable acid addition salts (hereinafter: the agents of the invention) have pharmacological activity and are useful as pharmaceuticals. In particular the agent of the invention exhibit human vanilloid antagonistic activity. More particularly, the agents of the invention, e.g. the compounds of examples 1 - 60 are active, e.g. at the human vanilloid receptor type 1 (VR1).

Vanilloid receptor interaction of the agents of invention is demonstrated by the following test 1.

Test I: Fluorescence assay

Cultures of Chinese Hamster Ovary (CHO) cells expressing human VR1 ion channels are prepared according to standard protocols [McIntyre et al., British Journal of Pharmacology 132: 1084-1094 (2001)]. The activity of test compounds are investigated using a fluorescence assay utilising calcium sensitive dyes to measure changes in intracellular calcium ion concentration. The cells are plated at a density of 40,000 per well on 96 well Costar black, clear bottomed plates cultured at 37°C in 5% CO₂ in MEM medium overnight. On the day of the assay, cells are incubated in 2µM fura-2/AM (Molecular Probes) made up in assay buffer [Hank's Balanced Salt Solution (HBSS, Invitrogen) containing 10mM N-2-(hydroxyethyl)piperazine-N'-[2-ethanesulfonic acid] (HEPES), pH 7.4] containing 0.01% pluronic F-127 for 40min at room temperature. After washing twice with assay buffer, 100µl assay buffer, or test compounds (range from 1nM to 10 µM final) where appropriate, are added to each well and the plate incubated for ten minutes at room temperature and then placed in a Molecular Devices Flexstation. The fluorescence is measured over 1min at 4s intervals using excitation wavelengths of 340 and 380nm and emission of 520nm. Human

vanilloid receptor 1 ion channels are stimulated by application of either the agonist capsaicin or low pH. At approximately 17s, 20µl of capsaicin made up at 6 fold the required final concentration were transferred to the cells. For pH experiments, 100µl HBSS alone pH 7.4 (containing test compounds) is added to the cells and 20µl of 60mM 2-[N-morpholino]ethane sulfonic acid (MES) in HBSS transferred to the cells. The pH of this solution is adjusted such that it gives the desired pH when diluted 1:6. The ratio of fluorescence intensities following excitation at 340 and 380nm is calculated for each time point. The agonist-evoked response is calculated as the mean of the ratios in the four time-points following stimulation minus the basal ratio.

In the above test the agents of the invention effectively block Ca-uptake in the range from about 1nM to about 10 µM.

In view of the above, the agent of the invention are useful in the prevention and treatment of diseases and conditions in which human VR1 activation plays a role or is implicated. Such conditions include in particular chronic pain, i.e. for the treatment of hyperalgesia and, in particular, for the treatment of severe chronic pain; neuropathic pain associated with post-herpetic neuralgia, amputations ("phantom limb pain"), reflex sympathetic dystrophy and other chronic nerve injuries; inflammatory pain, e.g. chronic inflammatory pain, bone and joint pain (osteoarthritis), cancer pain, myofascial pain (muscular injury, fibromyalgia) and perioperative pain (general surgery, e.g. associated with burns, sprains, fracture or the like, subsequent to surgical intervention, gynecologic surgery); or in asthma, for example, aluminosis, anthracosis, inflammatory diseases for example inflammatory airways disease, e.g. Chronic Obstructive Pulmonary Disease; asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis, and rhinitis; smooth muscle relaxants, e.g. for the treatment of spasm of the gastro-intestinal tract or uterus, e.g. in the therapy of Crohn's disease, ulcerative colitis or pancreatitis, inflammatory bowel disease, cystitis, e.g. interstitial cystitis, pancreatitis, and uveitis; inflammatory skin disorders and rheumatoid arthritis, inflammatory skin disorders, for example psoriasis and eczema.

Activity specifically as analgesic agents may be demonstrated in accordance with standard test methods, e.g. as described in the following test 2.

Test 2: Anti-hyperalgesic effects in a model of neuropathic pain in the rat

Peripheral neuropathy is induced by partial ligation of the left sciatic nerve. Mechanical hyperalgesia is assessed from paw withdrawal thresholds measured on the ipsilateral (ligated) and contralateral (non-ligated) hindpaws using standard paw pressure methods. Drug effects are studied 11-15 days post ligation. The mean paw withdrawal threshold \pm s.e.m. for the left (ligated) paw is compared to that of the right (non-ligated) paw.

Pharmaceutical Compound is administered, e.g. orally in 20 % cremophor/water in a volume of 1 ml. The post-drug percentage hyperalgesia values are obtained by comparison to the pre-drug value for the right (non-ligated) paw; this enables a true measure of the reduction in hyperalgesia to be obtained without the added complication of any drug effects on the right paw. Single oral administration of Pharmaceutical Compound produces a highly effective reversal of mechanical hyperalgesia in the partially denervated rat hind paw. Pharmaceutical Compounds produce a reversal of mechanical hyperalgesia at 30 mg/kg and show a rapid onset of activity with a long duration of action. Thus, Pharmaceutical Compounds are potent and efficacious anti-hyperalgesic agents following oral administration in a rat model of neuropathic pain.

For the above-mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.05 to about 150, preferably from about 0.1 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 0.5 to about 5000, preferably from about 1 to about 500mg of an agent of the invention, conveniently administered, for example, in divided doses up to four times a day or in sustained release form.

The agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.

The agents of the invention can be administered in vivo either alone or in combination with other pharmaceutical agents, e.g. agents effective in the treatment of diseases and conditions in which the human VR1 activation plays a role or is implicated including

cyclooxygenase-2 (COX-2) inhibitors, such as specific COX-2 inhibitors (e.g. celecoxib, COX189, and rofecoxib) or in general nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. acetylsalicylic acid, propionic acid derivatives), tricyclic antidepressants (e.g. Anafranil®, Asendin®, Aventyl®, Elavil®, Endep®, Norfranil®, Norpramin®, Pamelor®, Sinequan®, Surmontil®, Tipramine®, Tofranil®, Vivactil®, Tofranil-PM®), anticonvulsants (e.g. gabapentin), GABA_B agonists (e.g. L-baclofen), opioids and CB receptor agonists, e.g. CB₁ receptor agonists.

The pharmaceutical compositions for separate administration of the combination partners and for the administration in a fixed combination, i.e. a single galenical composition comprising at least two combination partners, according to the invention can be prepared in a manner known per se and are thus suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application.

Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of any condition mentioned above.

In still a further aspect the present invention provides a method for the treatment of any condition mentioned above, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.

The preferred compounds of formula I for use in accordance with the invention are that of Examples 1 and 2. These compounds are potent VR antagonists, in particular human VR1 antagonists. The IC₅₀ value for Example 1 in the Fluorescence assay (Test I) is 60nM and for Example 2, 50nM.

The following examples illustrate the invention.

Example 1: Preparation of 6-(4-Chloro-3-cyclopropylmethoxy-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one

a) Preparation of 4-Isopropyl-2-nitro-benzoic acid: A stirred solution of 2-nitro-4-cymene (8g, 0.0446mol) in t-butoxy bis(dimethylamino)methane (10g, 0.0574mol) is heated at 110°C for 10h. The deep red solution is cooled to room temperature and the excess reagent and by-products are removed under reduced pressure. The residue is dissolved in tert. butanol (600ml) and a solution of potassium acetate (51.35g, 0.372mol) in water (150ml) is added. Potassium permanganate (51.35g, 0.325mol) is added portion-wise to this mixture producing a slight exotherm. After 3h, the mixture is filtered through celite and the celite pad washed with water (500ml) and methanol (1000ml). The volatiles are evaporated under reduced pressure and the residue partitioned between ethyl acetate and water. The aqueous layer is acidified to pH3 using hydrochloric acid and the mixture is extracted with ethyl acetate (3x 150ml). The combined ethyl acetate extracts are washed with saturated brine, dried (MgSO₄), filtered and evaporated under reduced pressure to give 4-Isopropyl-2-nitro-benzoic acid as a brown solid. This is sufficiently pure to use in the next step without further purification. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 10.0 (1H, br s), 7.82 (1H, d, J = 8.0Hz), 7.64 (1H, d, J = 1.5Hz), 7.50 (1H, dd, J = 1.5, 8.0Hz), 3.05 (1H, m), 1.30 (6H, d, J = 6.9Hz).

b) Preparation of 4-Isopropyl-2-nitro-benzoic acid methyl ester: To a stirred solution of 4-isopropyl-2-nitro-benzoic acid (6.7g, 0.032mol) in dry DMF (100ml) at room temperature is added cesium carbonate (16.0g, 0.049mol). After 30 minutes, iodomethane (6.84g, 0.048mol) is added and the mixture is stirred at room temperature for 16h. The mixture is poured into water (500ml) and extracted with ethyl acetate (3x100ml). The combined EtOAc extracts are washed with water (200ml), saturated brine (100ml), dried (MgSO₄), filtered and evaporated to give a red oil. Purification by column chromatography on silica gel using cyclohexane/ethyl acetate (10:1) as eluant gave 4-isopropyl-2-nitro-benzoic acid methyl ester. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 7.70 (1H, d, J = 1.6Hz), 7.68 (1H, d, J = 7.9Hz), 7.50 (1H, dd, J = 1.6, 7.9Hz), 3.90 (3H, s), 3.05 (1H, m), 1.30 (6H, d, J = 6.9Hz).

c) Preparation of 2-Amino-4-isopropyl-benzoic acid methyl ester: To a stirred solution of 4-isopropyl-2-nitro-benzoic acid methyl ester (6.0g, 0.027mol) in methanol (200ml) at room temperature under argon is added 10% palladium on activated carbon (5.4g). The suspension is evacuated and purged with hydrogen three times and then stirred at room temperature for 18h. The reaction is then placed under argon atmosphere and filtered

through a pad of celite. The celite pad is washed with ethyl acetate and the filtrate and washings evaporated under reduced pressure to give a colourless oil. Purification by column chromatography on silica gel using cyclohexane/ethyl acetate (10:1) as eluant gave 2-amino-4-isopropyl-benzoic acid methyl ester. ^1H nmr (CDCl_3 , 400MHz) δH (ppm) 7.77 (1H, d, $J = 8.3\text{Hz}$), 6.53 (1H, dd, $J = 1.7, 8.3\text{Hz}$), 6.50 (1H, d, $J = 1.7\text{Hz}$), 5.67 (2H, br s), 3.85 (3H, s), 2.80 (1H, m), 1.21 (6H, d, $J = 6.9\text{Hz}$).

d) Preparation of 2-Amino-5-iodo-4-isopropyl-benzoic acid methyl ester: To a stirred solution of 2-amino-4-isopropyl-benzoic acid methyl ester (4.73g, 0.0245mol) in ethanol (100ml) at room temperature is added silver (I) sulfate (7.64g, 0.0245mol). A solution of iodine (6.23g, 0.0245mol) in ethanol (200ml) is added via a pressure-equalised dropping funnel at room temperature and the mixture is then stirred at room temperature for 1h. After filtration of the crude reaction mixture through a pad of celite, the ethanol is evaporated and the residue partitioned between water/ethyl acetate and extracted with ethyl acetate (3 x 100ml). The ethyl acetate extracts are combined and washed with saturated brine, dried (MgSO_4), filtered and evaporated to give a red solid. The crude product could be used directly or purified by chromatography on silica gel using cyclohexane/ethyl acetate (10:1) as eluant followed by recrystallisation from hexanes to give 2-Amino-5-iodo-4-isopropyl-benzoic acid methyl ester. ^1H nmr (CDCl_3 , 400MHz) δH (ppm) 8.25 (1H, s), 6.55 (1H, s), 5.69 (2H, br s), 3.85 (3H, s), 3.06 (1H, m), 1.19 (6H, d, $J = 6.8\text{Hz}$).

e) Preparation of 4-Chloro-3-fluorobenzeneboronic acid: A stirred solution of 4-bromo-1-chloro-2-fluorobenzene (25g, 0.119mol) and triisopropylborate (30.5ml, 0.131mol) in dry THF (500ml) under argon is cooled to -100°C and *n*-butyllithium (52.5ml of a 2.5M solution in hexanes, 0.131mol) is added dropwise over 15min. The reaction mixture is allowed to warm gradually to room temperature over 18h before it is quenched by the addition of 2M hydrochloric acid (250ml) and stirred at room temperature overnight. The THF is removed under reduced pressure, the aqueous residue is diluted with water (500ml) and the mixture is extracted with diethyl ether (3 x 200ml). The combined ether extracts are washed with saturated brine (200ml), dried (MgSO_4), filtered, evaporated and dried *in vacuo* to give a colourless solid - a mixture of 4-Chloro-3-fluorobenzeneboronic acid and the functionally equivalent cyclotriboroxane. ^1H nmr (d_6 -DMSO, 400MHz) δH (ppm) 8.33 (2H, br s), 7.75-7.67 (8H, m containing d, $J = 9.9\text{Hz}$), 7.63-7.58 (6H, m containing t, $J = 7.7\text{Hz}$).

f) Preparation of 4-Amino-4'-chloro-3'-fluoro-6-isopropyl-biphenyl-3-carboxylic acid methyl ester: To a stirred mixture of 4-chloro-3-fluorobenzeneboronic acid (12.3g, 0.071mol), 2-amino-5-iodo-4-isopropyl-benzoic acid methyl ester (18g, 0.0564mol) and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium (II) (1.35g, 1.65mmol) in dry DMF (250ml) under argon is added sodium carbonate (140ml of a 2M aqueous solution, 0.28mol). The mixture is heated at 80°C for 16h, cooled to room temperature and poured into diethyl ether (500ml). The ether layer is separated, washed with water (3 x 250ml) and then saturated brine (50ml), dried (MgSO₄), filtered and evaporated under reduced pressure to give a brown oil. Purification by column chromatography on silica gel using cyclohexane and then cyclohexane/ethyl acetate (50:1) as eluant gave pure product. The impure product-containing fractions are combined, evaporated and recrystallised from n-hexane with a trace of ethyl acetate to give further 4-Amino-4'-chloro-3'-fluoro-6-isopropyl-biphenyl-3-carboxylic acid methyl ester. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 7.64 (1H, s), 7.39 (1H, t, J = 7.9Hz), 7.05 (1H, dd, J = 1.9, 9.9Hz), 6.98 (1H, m), 6.63 (1H, s), 5.74 (2H, br s), 3.84 (3H, s), 2.95 (1H, m), 1.12 (6H, d, J = 6.8Hz).

g) Preparation of 6-(4-Chloro-3-fluoro-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one: Hydrogen chloride gas is bubbled through a solution of 4-amino-4'-chloro-3'-fluoro-6-isopropyl-biphenyl-3-carboxylic acid methyl ester (12.6g, 0.039mol) in dry acetonitrile (250ml) for 15min at room temperature. The bubbling is then stopped and the mixture heated at reflux for 2h, cooled to room temperature and the volatiles removed under reduced pressure. The colourless residue is poured into water (500ml) and sodium bicarbonate is added portion-wise until no further CO₂ evolution takes place. The mixture is extracted with dichloromethane (3 x 200ml) and the DCM extracts are combined and washed sequentially with water (50ml) and saturated brine (50ml), dried (MgSO₄), filtered and concentrated to about 50ml volume of DCM under reduced pressure. The resulting suspension is filtered, washed with n-hexane and dried to give the title compound as a colourless solid. The filtrate and washings were evaporated to give a beige solid which was sonicated in hexane/DCM, filtered, washed with hexane and dried to give further pure 6-(4-Chloro-3-fluoro-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 10.77 (1H, br s), 8.04 (1H, s), 7.70 (1H, s), 7.47 (1H, t, 7.9Hz), 7.13 (1H, dd, J = 1.9, 9.6Hz), 7.06 (1H, m), 3.10 (1H, m), 2.56 (3H, s), 1.22 (6H, d, J = 6.8Hz).

h) Preparation of 6-(4-Chloro-3-cyclopropylmethoxy-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one: To a stirred solution of 6-(4-chloro-3-fluoro-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one (6g, 0.0185mol) and cyclopropylcarbinol (7.35ml, 0.09mol) in dry N-methylpyrrolidinone (75ml) is added, portionwise, sodium hydride (60% dispersion on mineral oil, 3.6g, 0.09mol). When addition is complete, the mixture is heated at 60°C for 2h, cooled to room temperature and poured into water (300ml). The mixture is extracted with cyclohexane (2 x 100ml) to remove the mineral oil and then extracted with ethyl acetate (5 x 100ml). The ethyl acetate extracts are combined and washed with water (200ml) and then saturated brine (100ml), dried (MgSO₄), filtered and evaporated to give a colourless solid. This is recrystallised from ethyl acetate to give 6-(4-Chloro-3-cyclopropylmethoxy-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one after drying. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 11.51 (1H, br s), 8.06 (1H, s), 7.69 (1H, s), 7.41 (1H, d, J = 7.8Hz), 6.87-6.84 (2H, m), 3.91 (2H, d, J = 6.7Hz), 3.14 (1H, m), 2.57 (3H, s), 1.33 (1H, m), 1.22 (6H, d, J = 6.8Hz), 0.67 (2H, m), 0.39 (2H, m); Calc. C 69.01%, H 6.05%, N 7.32%, Found C 68.81%, H 6.07%, N 7.39%; HPLC RT = 6.8minutes (Phenomenex Luna C18 3 micron column (30 x 4.6mm); gradient elution: 10-100% MeCN in water (+0.08% formic acid) over 10 minutes at 3.0mL/minute); MH⁺ 383.

Example 2: Preparation of 6-(4-Chloro-3-propoxy-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one

a) Preparation of 4-Bromo-1-chloro-2-propoxybenzene: To a stirred solution of n-propanol (10.8ml, 0.143mol) in dry DMF (250ml) at 0°C is added, portion-wise, sodium hydride (60% dispersion on mineral oil, 5.72g, 0.143mol). When addition is complete, the mixture is stirred at 0°C until effervescence had subsided. The mixture of sodium propoxide thus produced is added to a cooled (0°C) solution of 4-bromo-1-chloro-2-fluorobenzene (10g, 0.048mol) in dry DMF (40ml) and then allowed to warm to room temperature over 18h. The volume of DMF is reduced *in vacuo* and the residue poured into water (500ml). The mixture is extracted with diethyl ether (3 x 200ml) and the ether extracts are combined and washed with water (250ml) and then saturated brine (100ml), dried (MgSO₄), filtered and evaporated to give a colourless oil. Purification by column chromatography on silica gel (110g) using cyclohexane as eluant gave 4-Bromo-1-chloro-2-propoxybenzene. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 7.20 (1H, d, J = 8.3Hz), 7.03 (1H, d, J = 2.1Hz), 7.01 (1H, dd, J = 2.1, 8.3Hz), 3.97 (2H, t, J = 6.5Hz), 1.91-1.82 (2H, m), 1.07 (3H, t, J = 7.4Hz).

b) Preparation of 4-Chloro-3-propoxybenzeneboronic acid: A stirred solution of 4-bromo-1-chloro-2-isopropoxybenzene (11.98g, 0.048mol) and triisopropylborate (12.26ml, 0.053mol) in dry THF (200ml) under argon is cooled to -78°C and n-butyllithium (21.1ml of a 2.5M solution in hexanes, 0.053mol) is added dropwise. The reaction mixture is allowed to warm gradually to room temperature over 8h before it is quenched by the addition of 2M hydrochloric acid (100ml) and stirred at room temperature overnight. Most of the THF is removed under reduced pressure and the mixture is diluted with diethyl ether (500ml). The ether layer is separated and washed with water (3 x 200ml) and then saturated brine (100ml), dried (MgSO₄), filtered and evaporated to give a colourless solid. This is sonicated with n-hexane, filtered and dried to give 4-Chloro-3-propoxybenzeneboronic acid as a 2:1 mixture with the corresponding cycloboroxane. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 7.72-7.68 (2H, m), 7.50 (1H, d, J = 7.8Hz), 7.39 (0.5H, d, J = 7.8Hz), 7.31 (0.5H, br d), 7.19 (0.5H, dd, J = 1.2, 7.8Hz), 4.59 (0.77H, br s, B(OH)₂ partially exchanged), 4.14 (2H, t, J = 6.5Hz), 4.04 (1H, t, J = 6.5Hz), 1.97-1.91 (2H, m), 1.90-1.83 (1H, m), 1.13 (3H, t, J = 7.4Hz), 1.08 (1.5H, t, J = 7.4Hz).

c) Preparation of 4-Amino-4'-chloro-6-isopropyl-3'-propoxy-biphenyl-3-carboxylic acid methyl ester: To a stirred mixture of 4-chloro-3-propoxybenzeneboronic acid (4.4g, 0.021mol), 2-amino-5-iodo-4-isopropyl-benzoic acid methyl ester (5.24g, 0.0164mol) and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium (II) (0.4g, 0.49mmol) in dry DMF (100ml) under argon is added sodium carbonate (41ml of a 2M aqueous solution, 0.082mol). The mixture is heated at 80°C for 16h, cooled to room temperature and poured into diethyl ether (500ml). The ether layer is separated, washed with water (3 x 200ml) and then saturated brine (50ml), dried (MgSO₄), filtered and evaporated under reduced pressure to give a brown syrup. Purification by column chromatography on silica gel using cyclohexane and then cyclohexane/ethyl acetate (50:1) as eluant followed by recrystallisation from n-hexane gave 4-Amino-4'-chloro-6-isopropyl-3'-propoxy-biphenyl-3-carboxylic acid methyl ester. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 7.66 (1H, s), 7.34 (1H, d, J = 8.0Hz), 6.80 (1H, d, J = 1.8Hz), 6.76 (1H, dd, J = 1.8, 8.0Hz), 6.64 (1H, s), 5.71 (2H, br s), 3.99 (2H, t, J = 6.5Hz), 3.84 (3H, s), 2.98 (1H, m), 1.87 (2H, m), 1.12 (6H, d, J = 6.8Hz), 1.07 (3H, t, J = 7.4Hz).

d) Preparation of 6-(4-Chloro-3-propoxy-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one: Hydrogen chloride gas is bubbled through a solution of 4-amino-4'-chloro-6-isopropyl-3'-

propoxy-biphenyl-3-carboxylic acid methyl ester (4.9g, 0.0136mol) in dry acetonitrile (100ml) for 15min at room temperature. The bubbling is then stopped and the mixture heated at reflux for 90min, cooled to room temperature and the volatiles removed under reduced pressure. The colourless residue is partitioned between water (500ml) and ethyl acetate (250ml) and sodium bicarbonate is added portion-wise until no further CO₂ evolution took place. The ethyl acetate phase is separated and washed sequentially with water (200ml) and saturated brine (50ml), dried (MgSO₄), filtered and evaporated under reduced pressure. The resulting colourless solid is suspended in boiling n-hexane (250ml) and ethyl acetate (250ml) is added until the solid dissolved. Upon cooling, this gave colourless crystalline product (6-(4-Chloro-3-propoxy-phenyl)-7-isopropyl-2-methyl-3H-quinazolin-4-one) and further pure material is recovered by evaporating the mother liquor. ¹H nmr (CDCl₃, 400MHz) δH (ppm) 10.36 (1H, br s), 8.06 (1H, s), 7.68 (1H, s), 7.41 (1H, d, J = 8.0Hz), 6.86 (1H, d, J = 1.8Hz), 6.83 (1H, dd, J = 1.8, 8.0Hz), 4.01 (2H, t, 6.5Hz), 3.15 (1H, m), 2.55 (3H, s), 1.91-1.85 (2H, m), 1.22 (6H, d, J = 6.8Hz), 1.08 (3H, t, J = 7.4Hz); Calc. C 68.01%, H 6.25%, N 7.55%; Found C 67.71%, H 6.00%, N 7.46%; Melting point 236°C; HPLC RT = 7.04minutes (Phenomenex Luna C18 3 micron column (30 x 4.6mm); gradient elution: 10-100% MeCN in water (+0.08% formic acid) over 10 minutes at 3.0mL/minute); MH⁺ 371.

In the following examples compounds of formula I wherein R² is isopropyl and R³ is methyl are prepared analogously to the Examples above:

Example	R ¹	MS	HPLC retention time [min]
3	4-chloro-phenyl	311.2 M-H-	4.93*
4	3,5-dichloro-phenyl	348.7 MH+	5.51*
5	I	329.1 MH+	4.1*
6	2,5-dichloro-phenyl	347.2 MH+	5.34*
7	3-methoxy-4-chloro-phenyl	343 MH+	4.92*
8	3-ethoxycarbonyl-4-methoxy-phenyl	381.4 MH+	4.15*
9	3-furyl	269.1 MH+	4.27*
10	4-chloro-3-ethoxy-phenyl	357 MH+	5.33*
11	3-ethoxy-4-methoxy-phenyl	352 M+	4.3*
12	benzo[1,3]dioxol-5-yl	322 M+	4.3*
13	2,2-difluorobenzo[1,3]dioxol-5-yl	359.5 MH+	5.24*
14	3-chloro-5-methoxy-phenyl	343.3 MH+	5.11*

15	3-chloro-5-ethoxy-phenyl	357.2 MH+	6.9*
16	4-chloro-3-isopropoxy-phenyl	371 MH+	6.7**
17	4-chloro-3-(2-methylpropoxy)-phenyl	385 MH+	7.5**
18	3,5-dichloro-4-methoxy-phenyl	377 MH+	6.82*
19	2,5-dimethyl-3-furyl	297 MH+	5.3*
20	3,5-dichloro-4-hydroxy-phenyl	363.1 MH+	5.75*
21	2,4-dichloro-5-ethoxy-phenyl	391.1 MH+	7.1**
22	5-methyl-isoxazol-3-yl	284.1 MH+	4**
23	4-chloro-3-cyclopropylmethoxy-phenyl	383 MH+	6.8**
24	4-chloro-3-fluoro-phenyl	331 MH+	5.7**
25	4-chloro-3-(2-methoxyethoxy)-phenyl	387 MH+	5.6**
26	4-chloro-3-butoxy-phenyl	385 MH+	7.5**
27	4-chloro-3-(tetrahydrofuran-2-ylmethoxy)-phenyl	413 MH+	6.7**
28	4-chloro-3-(3-dimethylaminopropoxy)-phenyl	414 MH+	3.74**
29	4-chloro-3-(2,2-dimethyl)-propoxy-phenyl	399 MH+	8.14**
30	4-chloro-3-propoxy-phenyl	371.2 MH+	7.05**
31	4-chloro-3-(tetrahydrofuran-3-ylmethoxy)-phenyl	413 MH+	6.1**
32	4-chloro-3-(2-dimethylaminoethoxy)-phenyl	397.3 M+	3.33**
33	4-chloro-3-(3-methylbutoxy)-phenyl	398.3 M+	7.96**
34	4-chloro-3-cyclopentoxo-phenyl	397.2 MH+	7.56**
35	3-bromo-5-methyl-phenyl	371 MH+	6.77**
36	4-chloro-3-(1-methylpyrrolidin-3-yloxy)-phenyl	412.4 MH+	3.66**
37	4-chloro-3-(fur-3-ylmethoxy)-phenyl	409.2 MH+	6.68**
38	4-chloro-3-(2-methyl-cyclopropylmethoxy)-phenyl	397.2 MH+	7.38**
39	4-chloro-3-(2-isopropoxyethoxy)-phenyl	414.4 M+	6.75**
40	4-chloro-3-(2-ethoxyethoxy)-phenyl	400.4 M+	6.34**
41	3-chloro-4-methyl-phenyl	327.2 MH+	6.44**

42	4-chloro-3-(2-phenethyloxy)-phenyl	433.2 MH+	7.62**
43	4-chloro-3-[2-(2-methoxyphenyl)ethoxy]-phenyl	463.3 MH+	7.72**
44	4-chloro-3-(2-cyclopropylethoxy)-phenyl	397.2 MH+	7.53**
45	4-chloro-3-(1-methyl-cyclopropyl-methoxy)-phenyl	399.3 M+	7.48**
46	4-chloro-3-cyclobutylmethoxy-phenyl	397.2 MH+	7.72**
47	4-chloro-3-propylsulfanyl-phenyl	387.2 MH+	7.36**
48	4-chloro-3-[2-(4-methoxy-phenyl)-ethoxy]-phenyl	463.3 MH+	7.49**
49	4-chloro-3-(1,1dimethyl-propoxy)-phenyl	398.5 M+	7.53**
50	4-chloro-3-(3-fluoro-propoxy)-phenyl	389 MH+	6.54**
51	4-chloro-3-[2-(3-methoxy-phenyl)-ethoxy]-phenyl	463.3 MH+	7.49**
52	4-chloro-3-(3-methylsulfanyl-propoxy)-phenyl	417.2 MH+	7.09**
53	4-chloro-3-methyl-phenyl	327.2 MH+	6.49**
54	4-chloro-3-[2-(2-methoxy-ethoxy)ethoxy]-phenyl	431.3 MH+	5.82**
55	4-chloro-3-[(Z)-propenyl]oxy]-phenyl	369 MH+	6.97**
56	4-chloro-3-(2-propoxy-ethyl)-phenyl	399 MH+	7.17**
57	4-chloro-3-allyloxy-phenyl	369 MH+	6.62**
58	4-chloro-3-(3-methoxy-butoxy)-phenyl	415.2 MH+	6.65**

Example 59: Preparation of 2-Amino-6-(4-chlorophenyl)-7-isopropyl-3H-quinazolin-4-one.

a) Preparation of 4-Amino-4'-chloro-6-isopropylbiphenyl-3-carboxylic acid: A suspension of 4-amino-4'-chloro-6-isopropylbiphenyl-3-carboxylic acid methyl ester [prepared analogously to examples above] (0.95 g, 3.13 mmol) in methanol (20 mL) under a nitrogen atmosphere was treated with 5M KOH solution (12 mL), and the mixture is heated at 80 °C for 1 h. Upon cooling to room temperature, the mixture is partitioned between ethyl acetate (50 mL) and water (100 mL) and extracted. The aqueous phase is washed with fresh ethyl acetate (50 mL). The aqueous phase is acidified to pH3 with conc. HCl solution, and extracted with ethyl acetate (2 × 50 mL). The combined organic layers are dried (anhydrous MgSO₄), filtered and

the solvent is removed under reduced pressure to afford the crude title compound as a brown semi-solid residue. This is used without further purification, although a small sample is purified by flash chromatography (1:1 ethyl acetate-hexanes) for analytical purposes. ^1H nmr (DMSO- d_6 , 400MHz) δH (ppm) 7.47-7.44 (3H, overlapping s and d), 7.27-7.25 (2H, dd, J = 0.8, 8.1 Hz), 6.79 (1H, s), 2.9-2.85 (1H, m), 1.09-1.07 (6H, d, J = 6.6 Hz).

b) Preparation of 6-(4-Chlorophenyl)-7-isopropyl-1H-benzo[d][1,3]oxazine-2,4-dione: A stirred suspension of 4-amino-4'-chloro-6-isopropylbiphenyl-3-carboxylic acid (0.8 g, 2.76 mmol) in anhydrous dioxane (15 mL) is treated at room temperature with trichloromethyl chloroformate (2.18 g, 11.04 mmol). The mixture is heated under reflux for 6 h. Upon cooling to room temperature, methanol (3 mL) is added and the mixture is concentrated by evaporation under reduced pressure. The resulting brown solid is recrystallized from absolute ethanol to afford the title compound as off-white crystals. ^1H nmr (DMSO- d_6 , 400MHz) δH (ppm) 7.47 (1H, s), 7.4-7.38 (2H, dd, J = 1.9, 6.7 Hz), 7.21-7.19 (2H, dd, J = 1.9, 6.7 Hz), 2.88-2.81 (1H, m), 0.97-0.96 (6H, d, J = 6.8 Hz).

c) Preparation of 2-Amino-6-(4-chlorophenyl)-7-isopropyl-3H-quinazolin-4-one: A stirred suspension of 6-(4-chlorophenyl)-7-isopropyl-1H-benzo[d][1,3]oxazine-2,4-dione (0.216 g, 0.68 mmol), 2-ethyl-2-thiopseudourea hydrobromide (0.126 g, 0.68 mmol) and Na_2CO_3 (0.145 g, 1.37 mmol) in MeCN (10 mL) is heated under reflux for 35 min. The condenser is removed and the bulk of the solvent is driven off. *m*-Xylene (6 mL) is added, the condenser is replaced and the temperature of the oil bath is raised to 150 °C. A small pellet of NaOH is added, and the mixture is heated under reflux for 2.5 h. Upon cooling to room temperature, the mixture is partitioned between 0.5M NaOH solution (150 mL) and ethyl acetate (50 mL) and extracted. The aqueous phase is extracted with fresh ethyl acetate (50 mL). The combined organic layers are backwashed with brine (100 mL) and dried (anhydrous MgSO_4). The solvent is removed under reduced pressure to afford the crude title compound as an off-white solid. This is recrystallized from absolute ethanol to afford pure compound. Mp 326-330 °C. ^1H nmr (DMSO- d_6 , 400MHz) δH (ppm) 10.89 (1H, s, exchanges with D_2O), 7.58 (1H, s), 7.5-7.47 (2H, dd, J = 1.8, 8.4 Hz), 7.33-7.31 (2H, dd, J = 1.8, 6.5 Hz), 7.18 (1H, s), 6.31 (2H, br s, exchanges with D_2O), 2.98-2.94 (1H, m), 1.13-1.12 (6H, d, J = 6.8 Hz). HPLC RT = 4.4minutes (Phenomenex Luna C18 3 micron column (30 x 4.6mm); gradient elution: 10-100% MeCN in water (+0.08% formic acid) over 10 minutes at 3.0mL/minute); MH+ 314.06 (100%).

In the following examples compounds of formula I wherein R² is isopropyl and R³ is NH₂ are prepared analogously to the above Example 59:

60	4-chloro-3-cyclopropylmethoxy-phenyl	384.2 MH+	5.08**
----	--------------------------------------	-----------	--------


HPLC conditions:

* Phenomenex Kingsorb 3 micron C18 column (30x4.6mm), gradient elution 10-100% MeCN in water (+0.1%TFA) over 10 minutes at 3.0mL/min.


** Phenomenex Luna reverse phase C18 3 micron 30 x 4.6mm; Gradient elution 10% MeCN in water (+0.08% formic acid) to 100% MeCN over 10 min (rate = 3.0 mL/min).

Claims

1. A compound of formula I






wherein



R^2 is hal; nitro; C_1 - C_6 alkylcarbonyl; C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl;

R^3 is C_1 - C_6 alkyl; C_1 - C_6 alkoxy or amino;

R^4 is H; hal; hydroxy; C_1 - C_6 alkyl; C_1 - C_6 alkoxy; C_1 - C_6 alkoxy C_1 - C_6 alkoxy; C_1 - C_6 alkoxy C_1 - C_6 alkoxy C_1 - C_6 alkoxy; C_1 - C_6 alkoxy C_1 - C_6 alkyl; halogeno C_1 - C_6 alkoxy; C_3 - C_7 cycloalkyl C_1 - C_6 alkoxy that may be substituted at the cycloalkyl residue by C_1 - C_6 alkyl; C_1 - C_6 alkoxycarbonyl; C_3 - C_6 alkenyl; $(C_1$ - C_6 alkyl) $_2$ N- C_1 - C_6 alkoxy; C_1 - C_6 alkyl-sulfanyl; C_1 -



wherein n is 0, 1, 2, 3, 4, 5 or 6;

R^5 , R^6 and R^{11} , independently, are H; hal; C_1 - C_6 alkoxy; or C_1 - C_6 alkyl;

R^7 , R^8 and R^{12} , independently, are H or C_1 - C_6 alkyl; and

R^9 and R^{10} , independently, are H or hal;

in free base or acid addition salt form.

2. A compound of formula II



wherein

R¹ and R² are as defined in claim 1.

3. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, comprising the steps of

a) for the production of a compound of formula I wherein R³ is not NH₂, reacting a compound of formula II



wherein

R¹ and R² are as defined in claim 1,

with a compound of formula III



wherein R³ is as defined in claim 1; or

b) for the production of a compound of formula I wherein R³ is NH₂, reacting a compound of formula IV



wherein R¹ and R² is as defined in claim 1,

with 2-ethyl-2-thiopseudourea hydrobromide;
and recovering the obtained compound, in free or in salt form.

4. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

5. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment or prevention of a disease or condition in which the vanilloid receptor activation plays a role or is implicated.

6. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

7. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment or prevention of a disease or condition in which vanilloid receptor activation plays a role or is implicated.

8. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment or prevention of a disease or condition in which vanilloid receptor activation plays a role or is implicated.

9. A method for treating or preventing a disease or condition in which vanilloid receptor activation plays a role or is implicated comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.

10. A pharmaceutical composition for the treatment or prevention of a diseases or condition in which vanilloid receptor activation plays a role or is implicated comprising a compound according to claim 1 and a carrier.

PCT Application
EP0311276



EP0311276